GERN: Geron Corp. Company Profile & Statistics

About

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.

Info & Links

CEO

John A. Scarlett

Headquarters

919 EAST HILLSDALE BOULEVARD, SUITE 250
FOSTER CITY, CA 94404, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

451

Employees

141

Geron Corp. Statistics

Valuation Measures

Market Capitalization²

2.29B

Enterprise Value

2.31B

Enterprise Value/EBITDA(ttm)

-10.74

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

79.15

Price to Book(mrq)

7.96

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

99.11%

Operating Margin(ttm)

-682.48%

Profit Margin(ttm)

-62980.81%

Return on Equity(ttm)

-67.53%

Return on Invested Capital(ttm)

-62.24%

Return on Assets(ttm)

-45.46%

Income Statement

Revenue(ttm)

29.48M

Revenue Per Share(ttm)

0.05

Gross Profit(ttm)

29.01M

EBITDA(ttm)³

-214.68M

Net Income Available to Common(ttm)

-201.19M

Diluted EPS(ttm)

-0.32

Share Statistics

Beta (5Y Monthly)

0.51

52-Week Change

103.23%

S&P 500 52-Week Change

23.87%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

604.50M

Dividend Yield

0.00%

Float⁴

586.37M

% Held by Insiders

3.00%

% Held by Institutions

73.71%

Balance Sheet

Total Cash(mrq)

341.63M

Total Cash Per Share(mrq)

0.57

Total Debt(mrq)

83.84M

Total Debt/Equity(mrq)

28.68%

Current Ratio(mrq)

2.89%

Quick Ratio(mrq)

2.74%

Book Value Per Share(mrq)

0.48

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.26

Free Cash Flow(ytd)

-175.49M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

GERN

Geron Corp.

Geron Corp. Profile